Related Experiment Video
Updated: Dec 1, 2025

Intratracheal Instillation of Stem Cells in Term Neonatal Rats
Published on: May 4, 2020
What is bronchopulmonary dysplasia and does caffeine prevent it?
1Division of Neonatology and Department of Pediatrics, Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, PA, United States.
Insights
Caffeine therapy reduces the risk of bronchopulmonary dysplasia (BPD) in premature infants by improving cardiorespiratory outcomes. However, further strategies are needed to fully prevent BPD in very low birth weight infants.
Area of Science:
- Neonatology
- Pediatric Pulmonology
- Pharmacology
Background:
- Bronchopulmonary dysplasia (BPD) is a severe complication of very premature birth.
- Lung immaturity, inflammation, and impaired repair drive BPD development.
- Current preventative strategies, including caffeine, do not eliminate BPD risk.
Purpose of the Study:
- To review the role of caffeine in preventing bronchopulmonary dysplasia.
- To explore the mechanisms by which caffeine reduces BPD risk.
- To highlight the need for novel BPD prevention methods.
Main Methods:
- Review of clinical and laboratory studies on BPD pathogenesis and caffeine therapy.
- Analysis of caffeine's cardiorespiratory and direct pulmonary effects.
- Evaluation of current preventative strategies for BPD.
Main Results:
- Caffeine initiated early significantly decreases BPD risk in very low birth weight infants.
- Benefits include reduced need for positive airway pressure and oxygen.
- Caffeine improves pulmonary mechanics and reduces PDA treatment, impacting inflammation, alveolarization, and angiogenesis.
Conclusions:
- Routine caffeine administration is recommended for most very low birth weight infants.
- Despite caffeine's benefits, BPD remains a significant challenge.
- Novel approaches are essential to further mitigate BPD risk in vulnerable infants.
Abstract:
Bronchopulmonary dysplasia (BPD) is among the most severe complications of very premature birth. Clinical and laboratory studies indicate that lung immaturity, inflammatory lung injury, and disordered lung repair are the primary mechanisms responsible for the development of BPD. Caffeine, initiated within the first 10 days after birth, is one of few drug therapies shown to significantly decrease the risk of BPD in very low birth weight infants. This benefit is likely derived, at least in part, from reduced exposure to positive airway pressure and supplemental oxygen with caffeine therapy. Additional cardiorespiratory benefits of caffeine that may contribute to the lower risk of BPD include less frequent treatment for a PDA, improved pulmonary mechanics, and direct effects on pulmonary inflammation, alveolarization, and angiogenesis. Routine administration of caffeine is indicated in the vast majority of very low birth weight infants. However, current preventative strategies including widespread use of caffeine do not avert BPD in all cases. As such, there is continued need for novel methods to further reduce the risk of BPD in very low birth weight infants.
Related Concept Videos
COPD: Management Using Bronchodilators and Corticosteroids
Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Pulmonary Cycle: Exhalation
Chronic Obstructive Pulmonary Disease-I: Introduction
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation

